Acamprosate calcium 333 MG Delayed Release Oral Tablet
1 INDICATIONS AND USAGE Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation ( 1 , 14 ). Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support ( 1 ).
american health packaging
ROUND WHITE 435
435 ROUND WHITE
Related Pills
Ranitidine 150 MG Oral Tablet
IVAX Pharmaceuticals, Inc.
Ranitidine 150 MG Oral Tablet
IVAX Pharmaceuticals, Inc.
mesalamine 800 MG Delayed Release Oral Tablet Zaldyon
Cadila Healthcare Limited
fluoxetine 20 MG as fluoxetine hydrochloride 22.4 MG Oral Capsule
Teva Pharmaceuticals USA Inc
Bupropion Hydrochloride 100 MG Oral Tablet
mylan pharmaceuticals inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING
ACAMPROSATE CALCIUM delayed-release tablets, 333 mg are white to off white, round, biconvex, enteric coated tablets, with “435” debossed on one side and plain on other side. Unit dose packages of 30 (5 x 6) NDC 60687-121-25 Storage and Handling Store at 20°C to 25°C (68°F to 77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken.
More pills like ROUND 435